Raymond James Financial
MXCT icon

Raymond James Financial’s MaxCyte MXCT Stock Holding History

Raymond James Financial’s Portfolio MXCT Stock Details MXCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-303
Closed -$661 – 6069
2025
Q2 		$661 Buy
+303
New +$734 ﹤0.01% 6635

Other funds holding MXCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
MFS
Mirabella Financial Services London, United Kingdom $1.05B AUM 22.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VP
Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return
MA
Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return
AIM
AXA Investment Managers Puteaux, France $37.1B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial's MXCT Position: Q3 2025 in Review

Raymond James Financial sold out of MaxCyte (MXCT) in Q3 2025, closing a stake of 303 shares — an estimated $661 sold.

Raymond James Financial first reported a position in MXCT in Q2 2025 and held it in 1 quarter. The position peaked at $661 in Q2 2025. 112 funds tracked by Wall St. Rank hold MXCT as of Q3 2025.

  • Raymond James Financial reported no remaining MaxCyte position as of Q3 2025 after selling out during the quarter.
  • Raymond James Financial sold 303 MaxCyte shares in Q3 2025, an estimated $661.
  • Raymond James Financial first reported a position in MaxCyte in Q2 2025 and held it in 1 quarter.
  • Raymond James Financial's MaxCyte position peaked at $661 in Q2 2025.
  • 112 funds tracked by Wall St. Rank held MaxCyte as of Q3 2025.

Based on Raymond James Financial's 13F filing for Q3 2025, filed 14 Nov 2025.